Mechanism of action and resistance to Trastuzumab Deruxtecan in patients with metastatic breast cancer: the DAISY trial

ABSTRACT: Trastuzumab deruxtecan (T-DXd) is an anti-HER2 (human epidermal growth factor receptor 2) antibody-drug conjugate which has previously shown a meaningful high efficacy in HER2-positive and HER2-low metastatic breast cancer (mBC). However, the mechanism of action of this drug remains partially unknown. DAISY (NCT04132960) is a phase II, open-label study that included patients with mBC whose disease progressed after at least one line of chemotherapy in the metastatic setting. Patients were enrolled in three cohorts according to HER2 expression determined by immunohistochemistry: HER2-overexpressing (n=68), HER2-low (n=72), and HER2-non expressing mBC (n=37). Patients were treated with T-DXd 5.4 mg/kg every 3 weeks until progression disease or unacceptable toxicity. In the per cohort analysi

ORGANISM(S): Homo sapiens (human)

SUBMITTER:  

PROVIDER: S-BSST974 | biostudies-other |

REPOSITORIES: biostudies-other